VEGFA and non-small cell lung carcinoma: Furthermore, the proportions of concomitant use of VEGF/VEGFR inhibitors with docetaxel in NSCLC patients were not balanced between the post-ICI and ICI-naïve groups, likely because of the proximity of the approval dates of ramucirumab and ICIs.